$5.7 Trillion and Climbing: What America’s Health Spending Surge Actually Signals

The number itself is almost too large to process. U.S. healthcare spending reached $5.7 trillion in 2025 — a 7.3% increase over the prior year, and the third consecutive year of growth above 7%. By 2034, CMS actuaries project that figure will approach $9 trillion, representing more than 20% of the entire U.S. economy.

But the number, on its own, is not the story. What is driving it, who is paying for it, and how the underlying dynamics are shifting — that is what providers need to understand.

The Counterintuitive Engine: Utilization, Not Prices

The default assumption when healthcare costs spike is that prices are rising. In this case, that assumption is largely wrong, and the distinction matters enormously for how providers should respond.

CMS actuaries are explicit: the sharp spending growth is not primarily driven by price increases. Cost growth has been moderate. What is actually happening is that Americans are consuming more healthcare — a utilization surge that reflects pent-up demand following the COVID-19 pandemic, when patients deferred care on a massive scale. The system is not getting more expensive per unit. It is delivering more units.

For providers, this reframes the strategic problem. If price inflation were the driver, the response would be focused on contract renegotiation, cost control, and margin protection. If utilization is the driver, the pressure falls on capacity, staffing, throughput, and care coordination. The workforce shortage — in nursing, in primary care, in behavioral health — is not just a human resources problem. In a utilization-driven spending environment, it is directly limiting revenue.

GLP-1s: The Drug Class Reshaping Everything

One factor that is genuinely price-driven is the explosion in GLP-1 prescribing. One in eight Americans now reports taking a GLP-1 medication. At approximately $1,000 per month per patient, the aggregate cost is enormous — CMS Deputy Director John Poisal has identified GLP-1s as a major contributor to the current spending spike, pushing growth rates up for both private insurance and Medicare.

The downstream consequences for providers are only beginning to emerge. GLP-1s are reducing obesity rates, improving glycemic control, and showing cardiovascular benefits — which means the volume of patients requiring bariatric surgery, complex diabetes management, and certain cardiac interventions is changing. Some of those changes benefit patients profoundly. Others create revenue disruptions that health systems have not fully modeled.

Pharmacy benefit structures are also under pressure. Payers are tightening prior authorization requirements, imposing step therapy protocols, and searching for ways to manage a drug class whose clinical benefits are real but whose cost trajectory is unsustainable at current prices. Providers who prescribe GLP-1s are navigating an increasingly complex authorization environment, and patients who cannot afford them are presenting with the untreated conditions those medications would have managed.

The Coverage Contraction Problem

While spending totals are rising, the share of the population with insurance is declining — a combination that creates a specific kind of pressure for providers.

In 2024, 91.8% of Americans had health insurance coverage. That figure is expected to fall to 90.8% in 2025, and to 90.5% by 2034. Two policy shifts are driving the contraction: the expiration of enhanced ACA subsidies that priced many Americans out of the individual market, and Medicaid enrollment reductions tied to the One Big Beautiful Bill Act’s new work requirements and restrictions on state financing mechanisms.

The problem is not just fewer insured patients in aggregate. It is the composition of who remains. When healthier, lower-utilization individuals drop coverage because premiums become unaffordable, the remaining insured pool skews toward sicker, higher-cost patients — a dynamic insurers themselves have confirmed, noting they are left with a smaller and higher-acuity population. Per-enrollee spending rises even as total enrollment falls. Providers absorb more uncompensated care. The math of the payer mix gets harder.

Medicare Is Now the Dominant Growth Engine

For hospitals, health systems, and post-acute providers, the payer mix trajectory has a clear direction: toward Medicare, and away from commercial insurance.

Medicare spending is projected to grow at 7.7% annually through 2034 — the fastest rate of any payer type — as the youngest Baby Boomers enter the program and the oldest require intensive, sustained care. By 2034, Medicare will account for 33% of all U.S. health spending, up from 31% in 2024. The employer-sponsored insurance share, historically the most generous payer and the one that cross-subsidizes Medicare and Medicaid shortfalls in hospital economics, is expected to shrink from 18% to 17% over the same period.

These shifts compound each other. More Medicare, less commercial, more uninsured — at the same time that utilization is climbing and workforce constraints are limiting capacity. The providers best positioned to navigate this environment are not necessarily the largest or the most sophisticated. They are the ones who have modeled these dynamics honestly and built operational strategies around the actual payer mix they will have in 2030, not the one they have today.

The Political Ceiling

National health spending is expected to reach 20.6% of GDP by 2034. No wealthy country spends at that level. The political response to date — primarily consisting of voluntary cost-containment commitments from healthcare industry stakeholders — has not materially affected the trajectory.

CMS actuaries noted that policymakers will need to continue exploring options for addressing significant financing challenges in a sector expected to account for more than one-fifth of the U.S. economy within a decade. That language, in a government actuarial report, is as close to an alarm as actuaries get. It signals that the current trajectory is not considered sustainable by the people whose job it is to model it.

For providers, the practical implication is that payment policy pressure is not going away. Value-based care contracts, site-of-care reimbursement adjustments, and prior authorization expansion are all instruments that payers — public and private — will reach for as spending growth continues to outpace economic growth. Building clinical and operational models that perform well under those pressures, rather than ones optimized for a fee-for-service environment that is gradually being dismantled, is the strategic imperative that $5.7 trillion makes urgently concrete.

Sources